Cargando…
Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRI(ca)Col1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib)
Transforming growth factor-β (TGF-β) plays a crucial role in the pathogenesis of Systemic Sclerosis (SSc) and other fibrotic disorders. TGF-β-mediated c-Abl and Src kinase activation induces strong profibrotic cascade signaling. The purpose of this study was to test in vivo the antifibrotic activity...
Autores principales: | Wermuth, Peter J., Jimenez, Sergio A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931634/ https://www.ncbi.nlm.nih.gov/pubmed/29718973 http://dx.doi.org/10.1371/journal.pone.0196559 |
Ejemplares similares
-
Control of mammary tumor differentiation by SKI-606 (bosutinib)
por: Hebbard, Lionel, et al.
Publicado: (2010) -
Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M., et al.
Publicado: (2012) -
Trust-Based Relational Intervention (TBRI): A Systemic Approach to Complex Developmental Trauma
por: Purvis, Karyn B., et al.
Publicado: (2013) -
Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567-4576
Publicado: (2013) -
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
por: Isfort, Susanne, et al.
Publicado: (2023)